Alcohol and drugs JSNA support pack Key data to support planning for effective drugs prevention, and recovery MILTON KEYNES MILTON KEYNES J8B
SUPPORTING INFORMATION This pack provides key performance and recovery outcomes information about your system with national data for comparison. It presents data from the Drug Treatment Monitoring System (NDTMS), the Treatment Outcomes Profile (TOP), the Drug Interventions Programme (DIP) and estimates of the prevalence of opiate and/or crack cocaine use. Although drug services treat dependence for all drugs, heroin users remain the group with the most complex problems, so separate data is provided for them. KEY FACTORS INFLUENCING YOUR TREATMENT OUTCOMES Data within this pack presents outcomes for clients during their time in and also longer-term recovery outcomes. The outcomes achieved while in can be demonstrated to be very good predictors of successful completion and non re-presentation especially housing and employment and abstinence from illicit drug use. In addition the latest successful completion and non re-presentation rates are a very good indicator of future performance in the PHOF indicators 2.5i and 2.5ii (successful completion of drug ) http://www.phoutcomes.info/public-health-outcomes-framework#gid/42/par/e24/ati/2/page/ Key factors influencing your outcomes 22-3 compared to 2-2 Non-opiate Completions Up Up Waiting times (proportion waiting under 3 weeks) No Change Non re-presentations Down 3% Down 3% VALUE FOR MONEY Drug addiction leads to significant crime, health and social costs. Evidence-based drug reduces these and delivers real savings, particularly in crime costs, but also in savings to the NHS through health improvements, reduced drug-related deaths and lower levels of blood-borne disease. This strong value for money case was endorsed by the Audit Office and is the foundation of central government s significant ongoing investment. To help local areas assess the benefits this investment brings to them, a local Value for Money tool produced by PHE will be available in October/November. This includes estimated crime and health savings, including number of crimes prevented. Designed to be flexible, the tool also allows areas to consider the consequences of disinvestment in terms of increased crime and disorder, poorer health outcomes, increased risk to communities and poorer outcomes for families with multiple needs. These products are based on work that has been approved by senior economists in the Home Office and Department of Health. PREVALENCE ESTIMATES The estimated number of opiate and/or crack users (OCU) and injectors in your area is set out below. Collectively, they have a significant impact on crime, unemployment, safeguarding children and welfare dependency. Prevalence estimates (Aged from 5-64) OCU Crack Injecting n 932 Rate per 5.67 Rate per n 298,752 8.67 846 5.5 26,792 7.59 43 2.5 7,627 4.95 22.34 93,4 2.7,2, 8 6 4 2 8-9 9- - OCU Crack Injecting PAGE 2 OF 6
WAITING TIMES This data shows the number of drug users who waited less than three or more than six weeks to start. Drug users need prompt help if they are to recover from dependence. efforts to keep waiting times low mean that the national average waiting time is less than one week. Keeping waiting times low will play a vital role in supporting recovery in local communities. Adults waiting under three weeks to start Adults waiting over six weeks to start 23 all initial waits 66,956 439 all initial waits 98% 9 9 - -2 2-3 TREATMENT ENGAGEMENT When engaged in, people use less illegal drugs, commit less crime, improve their health, and manage their lives better which also benefits the community. Preventing early drop out and keeping people in long enough to benefit contributes to these improved outcomes. As people progress through, the benefits to them, their families and their community start to accrue. The information below shows the proportion of adults in your area in 22-3 who have been in for three months or more a measure for effective engagement. Adults effectively engaged in 22-3 Growth Growth from from -2-2 425 6% 97% 48,368-3% 96% 92 3 87% 33,739 3% 88% 57 9 82,7-94% 9 8 7 6 5 4 - -2 2-3 Nonopiate EMPLOYMENT The data below shows the employment status of people starting in your area in 22-3. Being in work or undertaking meaningful activity is strongly associated with improved recovery outcomes, as is accessing education and training. However, the majority of people in drug and alcohol will require significant support to address their education, training and employment needs and to get them job ready. The data below helps illustrate the scale of this challenge in your area. PHE will supply more information on this to support your needs assessment, in the form of data matched with the Labour Market System (LMS) benefits data held by DWP. Joint working between your local and education and employment support services (Jobcentre Plus and Work Programme providers) is key to meeting this challenge. Employment status at the start of Regular employment Unemployed Long term sick or disabled 59 483 75 eligible clients 3 eligible clients 25,35 6% 9,74 58% 7,47 8 6 4 2 Employed Unemployed Sick / disabled PAGE 3 OF 6
IN TREATMENT OUTCOMES The data below is drawn from the Treatment Outcomes Profile (TOP), which tracks the progress drug users make in. This includes information on rates of abstinence from drugs and statistically significant reductions in drug use and injecting, and those successfully leaving with secure housing and in work. Data from NDTMS suggests that clients who stop using illicit opiates in the first six months of are almost five times more likely to complete successfully than those that continue to use. Abstinence abstinence Crack abstinence Cocaine abstinence 4 33 2 43% 57% 7 4 5 64% 8 6 4 2 Trend in performance 2- to 22-3 Crack Cocaine Significant reductions in use 4 significant reductions in use 28 3 23% 2 Crack significant reductions in use Cocaine significant reductions in use 3 2 3% Crack Cocaine Injecting use, housing need and employment Adults no longer injecting at review Adults successfully completing no longer reporting a housing need Adults working ten or more days in the month before successfully completing 7 6 88% 26 39% 2 3 Please note that all data is displayed here, regardless of TOP compliance in the local area 38 4 2 8 6 4 2 No longer injecting 4 No housing need Working SUCCESSFUL COMPLETIONS The data below shows the proportion of drug users who complete their free of dependence, the progress your area has made on people successfully completing, and those successfully completing who do not relapse and re-enter. The drug strategy asks local areas to increase the number of people successfully leaving having overcome dependence. Although many individuals will require a number of separate episodes spread over many years, most individuals who complete successfully do so within two years of entry. Also below is the proportion of adults who have been in for more than two years the data tells us that the likelihood of clients completing and not re-presenting decreases the longer they remain in over 2 years. Trend in performance 2- to 22-3 Successful completions as a proportion of total number in Proportion who successfully completed and did not return within 6 months Growth in successful completions since 2-2 adults in for two years or more 73% 93% 8 6% 8% 9% 3 4 8 9 88% -7% 39% 26% -3% 38% 54% 3 44% Non-opiate 5 Non-opiate Clients -5 - -2 2-3 Non-opiate PAGE 4 OF 6
RESIDENTIAL REHAB The data below shows the number of adult drug users in your area who have been to residential rehab during their latest period of (as a proportion of your whole and against the national proportion). Drug mostly takes place in the community, near to users families and support networks. Residential rehabilitation may be cost effective with someone who is ready for active change and a higher intensity at any stage of their, and local areas are encouraged to provide this option as part of an integrated recovery-orientated system. Number of adults who attended residential rehab 7 4,3 99% 98% PRESCRIPTION ONLY MEDICINE/OVER THE COUNTER MEDICINE (POM/OTC) People in for prescription-only medicines (POM) or over the counter medicines (OTC), and drug users who have a problem with these as well as illicit drugs are presented below. Health and public health commissioners will want to understand local need in relation to misuse of and dependence on prescription and over-the-counter medicines, so that together they can commission appropriate responses. Number of adults citing POM/OTC use Illicit use No illicit use Total 39 7% 5 9% 9 27,842 4% 4,63 32,445 7% 83% citing POM/OTC use CLUB DRUGS The data below covers the main club drugs reported by new entrants who are also using opiates (first table) or using club drugs and other drugs but not opiates (second table). users still dominate adult, and generally face a more complex set of challenges and are much harder to treat. Non-opiate-using, adult club drug users typically have good personal resources jobs, relationships, accommodation that mean they are more likely to make the most of. From April 23 NDTMS collected information on additional new psychoactive substances, and will report these next year. Number of adults new to citing club drug use and opiate use Methamphetamine Any club drug use 2 Proportion Proportion 24 26% 5 3 25 75 47 3 3% 37% 2 8 6 4 2 Methamph Number of adults new to citing club drug use (no additional opiate use) Methamphetamine Any club drug use 2 3 8 8% 8% 7% 966 78 28 83,46 3,7 3 23% 7% 6% 48% 9 8 7 6 5 4 3 2 Methamph Proportions of ecstasy, ketamine, GHB/GBL, methamphetamine and mephedrone as a percentage of any club drug use. Clients' citing the use of multiple club drugs will be counted once under each drug they cite. Therefore figures may exceed the total (labelled any club drug use) and proportions may sum to more than. 2 Any club drug use is a percentage of all new entrants. PAGE 5 OF 6
BLOOD-BORNE VIRUSES AND DRUG-RELATED DEATHS The data below shows the drug users in in your area who have had a hepatitis B vaccination and current or past injectors who have been tested for hepatitis C. Drug users who share injecting equipment can spread blood-borne viruses. Providing methadone and sterile injecting equipment protects them and communities, and provides long-term health savings. Although local drug-related death data is not provided, understanding and preventing deaths is an important measure of how well your recovery-orientated drug system is protecting people while increasing ambition. Adults new to eligible for a HBV vaccination who accepted one 53 eligible clients 37% 22,28 eligible clients 47% Of those: the proportion who started a course of vaccination the proportion who completed a course of vaccination 9% 4,989 23% 4,43 2 Previous or current injectors eligible for a HCV test who received one 85 63% 74,53 73% PARENTS AND FAMILIES The data below shows the number of drug users in who live with children; users who are parents but do not live with children; and users for whom there is incomplete data. This last item is included to help you consider the possible hidden (s) of drug-dependent parents, or those with childcare responsibilities in contact with local services. An estimated one in three of the English (64,862 people) has a child living with them at least some of the time. adults in who live with children Adults who live with children 25 23% 64,862 33% Adults who are parents but do not live with any children 73 3 4,532 2 Adults with incomplete data 4,69 77% 67% RESTRICTED STATISTICS You are reminded that the data provided in this document are official statistics to which you have privileged access in advance of release. Such access is carefully controlled and is provided for management, quality assurance, and briefing purposes only. Release into the public domain or any public comment on these statistics prior to official publication planned for 6th November 23 would undermine the integrity of official statistics. Any accidental or wrongful release should be reported immediately and may lead to an inquiry. Wrongful release includes indications of the content, including descriptions such as "favourable" or "unfavourable". If in doubt you should consult Malcolm Roxburgh or Jonathan Knight, via EvidenceApplicationTeam@phe.gov.uk, who can advise. Please prevent inappropriate use by treating this information as restricted, refrain from passing information on to others who have not been given prior access and use it only for the purposes for which it has been provided. If you intend to publish figures from the JSNA after 6th November you must restrict all figures under 5 and any associated figures to prevent deductive disclosure. The restricted status of this data will be lifted after the release of the Adult Drug Annual Report on 6th November 23. PAGE 6 OF 6